Discontinued — last reported Q1 '18
IQVIA Allowance for Doubtful Accounts Receivable (Current) decreased by 3.9% to $49.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 32.4%, from $37.00M to $49.00M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 8.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.00M | $30.00M | $33.00M | $30.00M | $28.00M | $31.00M | $36.00M | $33.00M | $28.00M | $27.00M | $34.00M | $30.00M | $40.00M | $41.00M | $42.00M | $37.00M | $37.00M | $45.00M | $51.00M | $49.00M |
| QoQ Change | — | -3.2% | +10.0% | -9.1% | -6.7% | +10.7% | +16.1% | -8.3% | -15.2% | -3.6% | +25.9% | -11.8% | +33.3% | +2.5% | +2.4% | -11.9% | +0.0% | +21.6% | +13.3% | -3.9% |
| YoY Change | — | — | — | — | -9.7% | +3.3% | +9.1% | +10.0% | +0.0% | -12.9% | -5.6% | -9.1% | +42.9% | +51.9% | +23.5% | +23.3% | -7.5% | +9.8% | +21.4% | +32.4% |